ArticleJAMA surgery2023
Feasibility and Clinical Utility of Prediction Models for Breast Cancer-Related Lymphedema Incorporating Racial Differences in Disease Incidence.
Article in JAMA surgery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- Consensus statement on non-cancer-related risk factors for development of secondary lymphedema.Medical oncology (Northwood, London, England) · 2024Guideline
- Racial and ethnic disparities in T helper 2-mediated inflammatory skin disorders.Skin health and disease · 2026Review
- Timing of Surgical Axillary Staging and Impact on Technical Success of Immediate Lymphatic Reconstruction Following Axillary Lymph Node Dissection.Annals of surgical oncology · 2026Article
- ASO Author Reflections: The Promise and Limits of Machine Learning in Lymphedema Risk Prediction.Annals of surgical oncology · 2026Article
- Association between chronic bronchitis and increased breast cancer risk in female patients.Public health action · 2026Article
- Using Machine Learning to Predict Breast Cancer-Related Lymphedema Following Axillary Lymph Node Dissection.Annals of surgical oncology · 2026Article
- Breast Cancer-Related Lymphedema: Nursing-Led Strategies - A Narrative Review.Journal of multidisciplinary healthcare · 2026Review
- AI-Empowered Mechanomedicine for Cancer-Related Lymphedema.Research (Washington, D.C.) · 2026Review
- Identification of chemotherapy-related risk factors for lymphedema in breast cancer patients using Lasso regression and model development.American journal of translational research · 2026Article
- Immediate lymphatic reconstruction (ILR) for prevention of secondary lymphedema after breast cancer surgery: a systematic review and meta‑analysis.Gland surgery · 2025Article
- Protective Factors Associated with Normal Lymphatic Function After Axillary Lymph Node Dissection for Breast Cancer Treatment.Annals of surgical oncology · 2025Article
- The association between allostatic load and lymphedema in breast cancer survivors.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Semantic-Attention Enhanced DSC-Transformer for Lymph Node Ultrasound Classification and Remote Diagnostics.Bioengineering (Basel, Switzerland) · 2025Article
- Lymphovenous anastomosis: microsurgical innovation and clinical outcomes in breast cancer-related lymphedema care.Frontiers in surgery · 2025Review
- The influence of non-cancer-related risk factors on the development of cancer-related lymphedema: a rapid review.Medical oncology (Northwood, London, England) · 2024Review
- Review
- GLP-1 receptor agonist as an effective treatment for breast cancer-related lymphedema: a case report.Frontiers in oncology · 2024Article
- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may reduce the risk of developing cancer-related lymphedema following axillary lymph node dissection (ALND).Frontiers in pharmacology · 2024Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
Importance: Breast cancer-related lymphedema (BCRL) is a common complication of axillary lymph node dissection (ALND) but can also develop after sentinel lymph node biopsy (SLNB). Several models have been developed to predict the risk of disease development before and after surgery; however, these models have shortcomings that include the omission of race, inclusion of variables that are not readily available to patients, low sensitivity or specificity, and lack of risk assessment for patients treated with SLNB. Objective: To create simple and accurate prediction models for BCRL that can be used to estimate preoperative or postoperative risk. Design, Setting, and Participants: In this prognostic study, women with breast cancer who underwent ALND or SLNB from 1999 to 2020 at Memorial Sloan Kettering Cancer Center and the Mayo Clinic were included. Data were analyzed from September to December 2022. Main Outcomes and Measures: Diagnosis of lymphedema based on measurements. Two predictive models were formulated via logistic regression: a preoperative model (model 1) and a postoperative model (model 2). Model 1 was externally validated using a cohort of 34 438 patients with an International Classification of Diseases diagnosis of breast cancer. Results: Of 1882 included patients, all were female, and the mean (SD) age was 55.6 (12.2) years; 80 patients (4.3%) were Asian, 190 (10.1%) were Black, 1558 (82.8%) were White, and 54 (2.9%) were another race (including American Indian and Alaska Native, other race, patient refused to disclose, or unknown). A total of 218 patients (11.6%) were diagnosed with BCRL at a mean (SD) follow-up of 3.9 (1.8) years. The BCRL rate was significantly higher among Black women (42 of 190 [22.1%]) compared with all other races (Asian, 10 of 80 [12.5%]; White, 158 of 1558 [10.1%]; other race, 8 of 54 [14.8%]; P < .001). Model 1 included age, weight, height, race, ALND/SLNB status, any radiation therapy, and any chemotherapy. Model 2 included age, weight, race, ALND/SLNB status, any chemotherapy, and patient-reported arm swelling. Accuracy was 73.0% for model 1 (sensitivity, 76.6%; specificity, 72.5%; area under the receiver operating characteristic curve [AUC], 0.78; 95% CI, 0.75-0.81) at a cutoff of 0.18, and accuracy was 81.1% for model 2 (sensitivity, 78.0%; specificity, 81.5%; AUC, 0.86; 95% CI, 0.83-0.88) at a cutoff of 0.10. Both models demonstrated high AUCs on external (model 1: 0.75; 95% CI, 0.74-0.76) or internal (model 2: 0.82; 95% CI, 0.79-0.85) validation. Conclusions and Relevance: In this study, preoperative and postoperative prediction models for BCRL were highly accurate and clinically relevant tools comprised of accessible inputs and underscored the effects of racial differences on BCRL risk. The preoperative model identified high-risk patients who require close monitoring or preventative measures. The postoperative model can be used for screening of high-risk patients, thus decreasing the need for frequent clinic visits and arm volume measurements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.